SKYSCRAPER-07 : A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab With or Without Tiragolumab (Anti-TIGIT Antibody), in Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

ThreePhase Three

18+Age Over 18

Oesophagus<br/>CancersCancer LocationOesophagus
Cancers

Systemic therapy,Treatment | Stomach and upper gastrointestinal tractOesophagus

Trial Overview Read MoreRead more

This phase III trial will evaluate how safe and effective two types of immunotherapy are, compared to a placebo, for the treatment of locally advanced oesophageal squamous cell cancer.
 

This trial is treating patients with oesophageal squamous cell cancer.

This is a systemic therapy trial.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.
  • You have previously been treated (or are currently being treated) on a clinical trial.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab With or Without Tiragolumab (Anti-TIGIT Antibody), in Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma

Commercial Sponsor

Hoffmann-La Roche

Summary

Eligible patients will be randomised into one of three Arms (A, B or C). In Arm A, patients will receive atezolizumab followed by tiragolumab. In Arm B, patients will receive atezolizumab followed by tiragolumab matching placebo. And, in Arm C, patients will receive matching placebos for both tiragolumab and atezolizumab.

Recruiting Hospitals Read MoreRead more

Olivia Newton-John Cancer Wellness & Research Centre
Heidelberg
Ms Samantha Chakar
samantha.chakar@austin.org.au
03 9496 3088

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next